Boehringer Ingelheim Dealt New Blow In Nearly Two Years Of Review For Pradaxa In Australia
This article was originally published in PharmAsia News
Australia’s Health Ministry calls for additional study of anticoagulant Pradaxa, dealing a fresh blow to Boehringer Ingelheim’s hopes of getting listed on the national reimbursement program nearly two years after initial regulatory approval.
You may also be interested in...
Data from the pilot program a “driving factor” in the agency’s decision against changing its recommendations for the blood thinner following reports of increased serious bleeding events.